Biodesix, Inc. (BDSX) financial statements and ratios from SEC XBRL: revenue $0.1B (TTM), net margin -39.8%, revenue growth 24.1% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $88.50M |
| Revenue (TTM) | $0.1B |
| Net Margin | -39.8% |
| Operating Margin (TTM) | -16.0% |
| Net Debt / EBITDA | -1.6 |
| Revenue Growth (YoY) | 24.1% |
| EPS Growth (YoY) | 1315.2% |
| FCF Growth (YoY) | -54.6% |
| Price / Book | 32.16 |
| Price / Sales | 2.95 |
| FCF Yield | -19.3% |
| Altman Z-Score | -5.97 (distress) |
| Industry P/E (Healthcare Services) | 25.4 |
| Sector P/E (Healthcare) | 21.9 |
BDSX overview · BDSX earnings · BDSX KPIs · BDSX documents · BDSX ownership · BDSX peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.